Selected article for: "economic cost and international license"

Author: Corey M Peak; Lauren M Childs; Yonatan H Grad; Caroline O Buckee
Title: Containing Emerging Epidemics: a Quantitative Comparison of Quarantine and Symptom Monitoring
  • Document date: 2016_8_31
  • ID: 2j4z5rp8_56
    Snippet: ). We calculate the number of days an infected individual was in quarantine but not yet infectious ( ! ) as surrogate for the marginal cost of quarantine over symptom monitoring. As abstract surrogates for cost-effectiveness, we calculate the absolute difference per quarantine day ! − ! ! and relative difference per . CC-BY-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed.....
    Document: ). We calculate the number of days an infected individual was in quarantine but not yet infectious ( ! ) as surrogate for the marginal cost of quarantine over symptom monitoring. As abstract surrogates for cost-effectiveness, we calculate the absolute difference per quarantine day ! − ! ! and relative difference per . CC-BY-ND 4.0 International license is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/072652 doi: bioRxiv preprint quarantine day ! ! !! ! ! ! ! and present these results in Figs S1 and S3. More concrete measures of cost-effectiveness would require economic and social considerations that are outside the scope of this paper.

    Search related documents:
    Co phrase search for related documents
    • absolute difference and International license: 1
    • absolute difference and relative difference: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absolute difference and symptom monitoring: 1, 2, 3
    • cc ND International license and cost effectiveness: 1, 2
    • cc ND International license and day number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • cc ND International license and infect individual: 1, 2
    • cc ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc ND International license and quarantine day: 1, 2
    • cc ND International license and relative difference: 1
    • cc ND International license and symptom monitoring: 1, 2, 3
    • cost effectiveness and day number: 1, 2, 3
    • cost effectiveness and International license: 1, 2, 3
    • cost effectiveness and marginal cost: 1, 2, 3
    • cost effectiveness and paper scope: 1
    • cost effectiveness and quarantine day: 1, 2, 3
    • cost effectiveness and relative difference: 1
    • cost effectiveness and symptom monitoring: 1, 2, 3
    • day number and quarantine day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • day number and symptom monitoring: 1, 2